Addiction recovery of opioid dependent patients treated with injectable subcutaneous depot buprenorphine (BUVIDAL®) - ARIDE

niversitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie (W37), Zentrum für Interdisziplinäre Suchtforschung (ZIS)0 sites426 target enrollmentMarch 6, 2020

ConditionsF11.2

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: F11.2
Sponsor: niversitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie (W37), Zentrum für Interdisziplinäre Suchtforschung (ZIS)
Enrollment: 426
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 6, 2020

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

niversitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie (W37), Zentrum für Interdisziplinäre Suchtforschung (ZIS)

Eligibility Criteria

Inclusion Criteria

•(1\) Opioid dependence (F11\.2\) according to ICD\-10; (2\) Minimum age of 18 years; (3\) Ability to follow the study conditions; (4\) Signed written informed consent.

Exclusion Criteria

•(1\) Existing contraindications according to the patient's specialist information to use BUVIDAL® (e.g. hypersensitivity to the active substance, severe respiratory failure, severe liver dysfunction, acute alcoholism or delirium tremen); (2\) patient already in substitution treatment with BUVIDAL®; (3\) Predictable reasons for early dropout (e.g. detention, planned place of residence and change of doctor)